0

Mitsubishi Tanabe Pharma Corp (4508) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Publisher Name :
Date: 17-May-2017
No. of pages: 116

Summary

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, is a pharmaceutical company. The company identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines. The company major products include remicade, simponi, tenelia, ceredist and lexapro. Mitsubishi Tanabe major products include flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It also offers fine chemicals, information services, real-estate leasing and advertising, among others. The company along with its subsidiaries operates in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp (4508) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
– The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
– The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
– Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
– Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
– Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of content
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 13
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 21
Venture Financing 21
Forge Therapeutics Raises USD15 million in Series A Financing 21
Rigontec Raises Additional USD16.7 Million in Series A Financing 22
miRagen Therapeutics Raises USD41 Million in Series C Financing 23
Thrasos Therapeutics Raises USD21 Million in Series D Financing 24
Covagen Raises US$50.3 Million In Series B Financing 26
F-Star Alpha Raises US$13 Million In Series A Financing 28
Thrasos Therapeutics Raises US$35 Million In Venture Financing 29
Genocea Biosciences Raises US$30 Million In Series C Financing 31
GenKyoTex Raises US$26 Million In Extended Series C Financing 33
Syndexa Pharma Secures Additional Financing In Series B1 Round 35
GenKyoTex Secures US$21 Million In Series C Financing 36
f-star Secures US$21.7 Million In Financing Round 37
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 38
Partnerships 40
Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 40
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 41
Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 43
Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 44
Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 44
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 45
Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 46
Medicago Enters into Contract with Public Health Agency of Canada 47
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 47
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 48
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 49
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 50
AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 51
Medicago Enters Into Co-Development Agreement With A Global Pharma Company 52
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 53
Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 54
Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 55
Medicago Enters Into Co-Development Agreement With Cellectis 56
X-BODY Enters Into Research Agreement With Tanabe Research Labs 56
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 57
Medicago Enters Into Research Collaboration With USAMRIID 58
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 59
Merger 60
Bensis To Merge With Japanese Red Cross Plasma Fractionation Center 60
Licensing Agreements 60
Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 60
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 61
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 62
AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 63
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 64
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 65
BioInvent Extends Licensing Agreement With Mitsubishi Tanabe Pharma For Therapeutic Antibodies 66
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 67
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 68
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 69
Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 71
Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 72
OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 72
Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 73
Mitsubishi Tanabe Pharma Enters Into Licensing Agreement With Toray For TRK-820 74
Handok Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe pharma 75
Equity Offering 76
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 76
Medicago Announces Private Placement Of Common Stock For US$3.4 Million 77
Medicago Completes Second Tranche Of Private Placement Of Shares For US$11 Million 78
Medicago Completes Private Placement Of Common Stock For US$24.5 Million 79
Medicago Completes Public Offering Of Units For US$17.72 Million 80
Asset Transactions 82
Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 82
Acquisition 83
Nipro to Acquire Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 83
CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 84
Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For US$ 172 Million In Going Private Transaction 85
Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 87
Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 89
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 90
Mitsubishi Tanabe Pharma Corp - Key Competitors 93
Key Employees 94
Locations And Subsidiaries 95
Head Office 95
Other Locations & Subsidiaries 95
Recent Developments 99
Strategy And Business Planning 99
Apr 01, 2016: MT Pharma Singapore Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in Singapore 99
Feb 23, 2016: Mitsubishi Tanabe Pharma Enhances Operations in the United States 100
Financial Announcements 101
May 10, 2017: Mitsubishi Tanabe Pharma Reports Revenue Of JPY424 Billion In Fiscal 2017 101
Aug 02, 2016: Mitsubishi Tanabe Pharma Announces Financial Results for the First Three Months of the Fiscal year ending March 31, 2017 102
Feb 03, 2016: Mitsubishi Tanabe Pharma Reports Net Sales Of JPY340.9 Billion For The Nine Months Ended December 31, 2015 104
Government and Public Interest 105
Jun 06, 2016: Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund 105
Jun 06, 2016: GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com 106
Product Approvals 108
Aug 30, 2016: FDA Accepts Mitsubishi Tanabe Pharma's NDA Filing for Edaravone to Treat ALS 108
Jun 20, 2016: Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States 109
Clinical Trials 110
Jun 01, 2016: Minerva Neurosciences to Present data on MIN-117 110
May 26, 2016: Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder 111
Apr 20, 2016: Mitsubishi Tanabe Pharma Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting 112
Feb 22, 2016: Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder 113
Other Significant Developments 114
Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma Strengthening business development in the ASEAN region 114
Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN region 115
Appendix 116
Methodology 116
About GlobalData 116
Contact Us 116
Disclaimer 116

List of Tables
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Mitsubishi Tanabe Pharma Corp, Deals By Therapy Area, 2011 to YTD 2017 11
Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 13
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Forge Therapeutics Raises USD15 million in Series A Financing 21
Rigontec Raises Additional USD16.7 Million in Series A Financing 22
miRagen Therapeutics Raises USD41 Million in Series C Financing 23
Thrasos Therapeutics Raises USD21 Million in Series D Financing 24
Covagen Raises US$50.3 Million In Series B Financing 26
F-Star Alpha Raises US$13 Million In Series A Financing 28
Thrasos Therapeutics Raises US$35 Million In Venture Financing 29
Genocea Biosciences Raises US$30 Million In Series C Financing 31
GenKyoTex Raises US$26 Million In Extended Series C Financing 33
Syndexa Pharma Secures Additional Financing In Series B1 Round 35
GenKyoTex Secures US$21 Million In Series C Financing 36
f-star Secures US$21.7 Million In Financing Round 37
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 38
Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 40
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 41
Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 43
Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 44
Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 44
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 45
Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 46
Medicago Enters into Contract with Public Health Agency of Canada 47
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 47
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 48
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 49
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 50
AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 51
Medicago Enters Into Co-Development Agreement With A Global Pharma Company 52
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 53
Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 54
Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 55
Medicago Enters Into Co-Development Agreement With Cellectis 56
X-BODY Enters Into Research Agreement With Tanabe Research Labs 56
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 57
Medicago Enters Into Research Collaboration With USAMRIID 58
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 59
Bensis To Merge With Japanese Red Cross Plasma Fractionation Center 60
Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 60
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 61
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 62
AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 63
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 64
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 65
BioInvent Extends Licensing Agreement With Mitsubishi Tanabe Pharma For Therapeutic Antibodies 66
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 67
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 68
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 69
Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 71
Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 72
OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 72
Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 73
Mitsubishi Tanabe Pharma Enters Into Licensing Agreement With Toray For TRK-820 74
Handok Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe pharma 75
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 76
Medicago Announces Private Placement Of Common Stock For US$3.4 Million 77
Medicago Completes Second Tranche Of Private Placement Of Shares For US$11 Million 78
Medicago Completes Private Placement Of Common Stock For US$24.5 Million 79
Medicago Completes Public Offering Of Units For US$17.72 Million 80
Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 82
Nipro to Acquire Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 83
CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 84
Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For US$ 172 Million In Going Private Transaction 85
Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 87
Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 89
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 90
Mitsubishi Tanabe Pharma Corp, Key Competitors 93
Mitsubishi Tanabe Pharma Corp, Key Employees 94
Mitsubishi Tanabe Pharma Corp, Other Locations 95
Mitsubishi Tanabe Pharma Corp, Subsidiaries 95

List of Figures
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 13

News

  • Understanding the Need For Travel Vaccination
  • If you are getting ready for a particular trip that can see you away from your house for about a month or so, then it is necessary for you to take the help of travel vaccinations. Not ...
  • The Work Of The Ophthalmology Specialist
  • When we consider ophthalmology as a branch of science, it is actually about the treatment as well as getting to diagnose the different kinds of diseases and the disorder that is to ...
  • The Process Of Dental Implants And The Subsequent Recovery
  • In the United States of America, the fear of going to a dentist happens to rank number one on the list of children as well as adults. Most of the people are actually concerned when ...
  • The medication that can help the rural population
  • It is not always that you get to see world class hospitals in the rural areas, be it America or any other country. Hence, it is important that people actually take the help of tele-medication, ...
  • The Future of Telemedicine & Its Use
  • When talking about telemedicine, you do get to realize that it is the healthcare of the future. Most of the people do not realize the implications, and for more so the time, telemedicine ...

Get Updates

Share This Post

Recent Posts

© 2021 RnR Company Profiles. All rights reserved.